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Abstract
The causes of age-related macular degeneration (AMD) are not well understood. Due to demographic shifts in the
industrialized world a growing number of people will develop AMD in the coming decades. To develop treatments
it is essential to characterize the disease’s pathogenic process. Over the past few years, numerous studies have
focused on the role of chemotactic cytokines, also known as chemokines. Certain chemokines, such as CCL2 and
CX3CL1, appear to be crucial in subretinal microglia and macrophage accumulation observed in AMD, and partici-
pate in the development of retinal degeneration as well as in choroidal neovascularization. This paper reviews the
possible implications of CCL2 and CX3CL1 signaling in AMD. Expression patterns, single nucleotide polymorphisms
(SNPs) association studies, chemokine and chemokine receptor knockout models are discussed. Future AMD treat-
ments could target chemokines and/or their receptors.
Introduction
Age-related macular degeneration (AMD) is the leading
cause of legal blindness in the developed world [1]. The
pathology is characterized by lesions of photoreceptors,
retinal pigment epithelium (RPE), Bruch’s membrane
(BM) and choriocapillaris [2]. Physiologically, the RPE
phagocytoses, degrades and recycles photoreceptor outer
segments, and clears the debris through the underlying
BM into the choroidal circulation. RPE cells selectively
transport nutrients from the choroidal capillaries to the
outer retina (external hemato-retinal barrier). In the
early stages of AMD changes in RPE pigmentation and
the excessive presence of yellowish-white subretinal
deposits called drusen are clinically observable (fundo-
scopy) [2,3]. Drusen are composed of lipids and proteins
[4], located on the BM, they are partially covered by the
RPE. It is believed that drusen are formed because of a
transport defect between the RPE and the choriocapil-
laries or as a result of degenerating RPE cells [5]. There
are two clinical forms of late AMD: the fast progressing
exudative form defined by choroidal neovascularisation,
responsible for the majority of legal blindness in AMD,
and the more slow progressing atrophic form character-
ized by RPE atrophy, photoreceptor degeneration and
choroidal involution and obliteration [6,7]. Some of
these features can be simulated in a variety of animal
models [8], but no animal model has consistently repro-
duced AMD.
In recent years, there has been increasing evidence for
an inflammatory component in AMD. Drusen deposits
have been reported to contain immune complexes, com-
plement factors, major histocompatibility complex
(MHC) and amyloid oligomers, among others [5,9-12].
A more recent discovery, that AMD is associated with a
polymorphism of complement factor H (CfH) [13-15], a
polymorphism that leads to an overactivation of the
complement system [16,17], emphasizes the importance
of inflammatory mediators in AMD. Nevertheless, it
remains unclear how the over-activation of the comple-
ment system leads to AMD.
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Microglial cells (MC) are the resident macrophages of
the central nervous system (CNS). In the eye they are
only located in the inner retina [18,19]. The subretinal
space is physiologically devoid of MCs or macrophages
(Mj) in healthy young adult subjects. In AMD, MC and
Mj are activated [9,20] and accumulate in the subretinal
space [19,21]. Interestingly, activated complement frac-
tion C3 and C5 participate in neutrophil and macro-
phage recruitment to the subretinal space in a choroidal
neovascularization model [22]. A similar mechanism
might participate in retinal/choroidal inflammation in
AMD. The prolonged presence of MC/Mj in the sub-
retinal space is associated with photoreceptor degenera-
tion [19,23] and the development of choroidal
neovascularization in animal models [24,25]. This is pos-
sibly because MC/Mj are an important source of cyto-
kines and angiogenic factors like VEGF [26,27].
Interfering with subretinal MC/Mj accumulation might
therefore be a promising avenue in the treatment of
AMD, but the mechanisms of subretinal MC/Mj cell
accumulation remain unclear.
Chemokines constitute a family of structurally related
chemotactic cytokines that direct the migration of leuko-
cytes throughout the body, both under physiological and
pathological conditions [28]. CCL2 signaling through
CCR2, and CX3CL1 signaling through CX3CR1 are key
factors in Mj recruitment to a tissue lesion [29,30]. In
this review, we discuss the possible role of CCL2/CCR2
and CX3CL1/CX3CR1 axes in MC/Mj homeostasis in
the healthy eye and in AMD. We review data describing
the expression of these chemokines and their receptors
in the retina, polymorphism studies in AMD, animal
chemokine and chemokine receptor knockout models
presenting drusen formation, and photoreceptor degen-
eration or choroidal neovascularisation.
CX3CL1, CX3CR1, CCR2 and CCL2 expression in the retina
In the blood, chemokine receptors CCR2 and CX3CR1
identify two functional subsets of murine blood mono-
cytes: “inflammatory” monocytes, which express both
receptors, and non-inflammatory monocytes, which only
express CX3CR1 [31]. CCL2 and CX3CL1 released by
tissue lesions participate in the recruitment of mono-
cytes and in local inflammation [29,30].
CX3CL1 is an atypical chemokine. It is expressed as a
transmembrane protein, which can be cleaved by pro-
teases into a soluble form that has chemotactic properties
[32]. In its transmembrane form, CX3CL1 mediates
integrine-like intracellular adhesion. Unlike many promis-
cuous chemokines, it only signals through the CX3CR1
receptor [33]. In the eye, it is constitutively expressed in
retinal neurons and in the RPE [34] CX3CL1 can also be
induced in microvascular endothelial cells [34]. In the
retina, the vast majority of resident “quiescent” MCs
express CX3CR1 in newborn (PN6) and adult mice (6 to
18 months) [19,35]. Immunohistochemistry reveals simi-
lar results in humans [19]. Contrary to a previous report,
the use of CX3CR1-specific antibody in humans and
experiments with Cx3cr1GFP/+ mice [36] failed to find sig-
nificant CX3CR1 expression in RPE cells in vivo [37].
MCs are the only cells in the retina that express CX3CR1
under physiological conditions.
CCL2 expression in the retina and RPE is very low in
healthy young adult animals [38], but increases in acute
inflammation [23,39,40], with aging [38] and under oxi-
dative stress in the RPE [41].
Recent evidence suggests that subretinal MC/Mj
induce CCL2 and CCL5 in the RPE [42]. CCL2 mainly
signals through CCR2 [43]. There is no direct evidence
of CCR2 expression by retinal MCs or macrophages in
the retina. However, it has been shown that CCL2/
CCR2 signaling is involved in monocyte or MC recruit-
ment after laser injury [44,45] and aging [45] in knock-
out mice. This suggests that CCR2-expressing
monocytes or MCs are present at some point in these
models. In the brain, CCR2 expression has been
reported to be very low in healthy rat CNS microglia,
but large numbers of CCR2 positive MC/Mj are found
in acute inflammation [46]. To summarize, CX3CL1 and
CX3CR1 are constitutively and robustly expressed in the
retina and might have a role in retinal homeostasis. In
contrast, CCL2 is expressed at low levels in the healthy
young adult, but increases with age and injury. A very
recent clinical study shows that elevated intraocular
CCL2 levels are associated with exudative AMD [47].
CCL2 might therefore play a role in monocyte and
microglial cell recruitment to the subretinal space with
age and in AMD.
CX3CR1, CCR2 and CCL2 single nucleotide polymorphisms
(SNPs) AMD
Several studies have examined SNPs of the chemokine
system and AMD susceptibility. The T280M allele of
the CX3CR1 gene has been shown to be associated with
AMD in a group of Caucasian patients recruited in the
Washington D.C. area [37]. We replicated this associa-
tion in a group of C-aucasian patients recruited in Paris
[19] and a similar association has recently been found in
Han Chinese patients recruited in Nantong [48]. Pre-
vious studies show that the M280 polymorphism pro-
vokes loss of chemotaxis [49] or increases adherence to
its ligand [50]. Therefore, dysfunctional CX3CL1/
CX3CR1 signaling might play a role in AMD (see
below). No evidence was found of an association
between common genetic variations of CCR2, and CCL2
and AMD [51].
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The Cx3cr1-/- mouse model of AMD
As the T280M allele of the CX3CR1 leads to dysfunc-
tional monocyte migration [19] and is associated with
AMD [19,37,48], several groups have studied Cx3cr1-/-
mice to decipher the effect of CX3CR1 dysfunction on
ocular homeostasis. As with monocytes bearing the
T280M allele, Cx3cr1-/- MCs display inhibited migration
[52] when compared with CX3CR1 competent MCs. We
have shown that Cx3cr1-/- mice spontaneously accumu-
late subretinal MC/Mj with age in the absence of
photoreceptor degeneration [19]. Furthermore, an
increased accumulation of subretinal MC/Mj is found
after light injury in comparison to a wildtype control
group [53]. These results stand in sharp contrast to
observations of inflamed peripheral tissue, where
Cx3cr1-/- mice similar to other chemokine receptor
knockouts present an inhibition of Mj accumulation
[30].
It has since been recognized that subretinal MC/Mj
also accumulate in wild type mice at a more advanced
age [54], suggesting that dysfunction of certain chemo-
kines and possible other factors accelerates a physiologi-
cal process leading to MC/Mj accumulation at an
earlier age in Cx3cr1-/- mice as compared to controls.
Ng et al. [55] showed that normal animal facility light-
ing conditions induced subretinal MC/Mj accumulation
in the absence of photoreceptor degeneration in albino
strains. Furthermore they show that subretinal MC/Mjs
are cleared from the subretinal space when light stimu-
lus is removed. These observations suggest that MC/
Mjs migrate to the subretinal space and are subse-
quently cleared once the stimulus is removed in the
absence of primary pathological photoreceptor or RPE
lesions. It remains unclear if this clearance is due to
apoptosis of the subretinal MC/Mj or to migration
from the subretinal space. In retinal degeneration, where
severe degeneration occurs, we observed an egress of
rhodopsin laden MC/Mjs from the subretinal space
[53], suggesting that MC/Mjs can leave the subretinal
space by migration. The migratory deficit observed in
Cx3cr1-/- microglia [52] might contribute to the reduced
clearance from the subretinal space and therefore accel-
erate the accumulation, as observed in aged Cx3cr1-/-
mice. Nevertheless, it cannot be excluded that reduced
subretinal MC/Mj apoptosis plays a role in subretinal
MC/Mj accumulation.
In Cx3cr1-/- mice, the resulting prolonged presence of
subretinal MC/Mj in the subretinal space is associated
with excessive OS phagocytosis by the MC/Mjs, which
subsequently ingest intracellular lipids [19,56]. These
subretinal MC/Mj “foam cells” are the origin of the
drusen-like deposits observed in the clinical observation
of Cx3cr1-/-mice [19] and have recently been reported
in Ccl2-/- mice [45] (see below). Similarly, CX3CR1-
positive bloated subretinal microglial cells are found in
the eyes of AMD patients [19,21]. Recent reports sug-
gest that drusen appearance in patients with AMD is
not solely caused by sub-RPE deposits, but also by sub-
retinal drusenoid deposits [57-59] not unlike the lesions
observed in Cx3cr1-/- and Ccl2-/- mice. It is tempting to
speculate that these drusenoid deposits are the conse-
quence of accumulated debris from subretinal MC/Mj
“foam cell” apoptosis. In consequence, drusen might
evolve from subretinal deposits which are subsequently
covered by the RPE. There are several lines of evidence
supporting this hypothesis: drusen contain numerous
degenerating organelles, the origin of which may be sub-
retinal MC/Mj [4]. Moreover, drusen contain CX3CR1,
apolipoprotein E, complement factors, and the major
histocompatibility complex (MHC) [5,9-12,19], all of
which can be expressed by MC/Mj [19,60-62]. The
debris and inflammatory proteins found in drusen may
originate in part from MC/Mj additionally to RPE
debris.
Another consequence of the prolonged presence of
Cx3cr1-/- MCs in the subretinal space is photoreceptor
cell death [19,53] and changes in RPE structure and dis-
tribution [42]. In Cx3cr1-/- mice on a pigmented C57Bl6
background, photoreceptor degeneration of about 25-
30% is observed in 18-month-old mice as compared to
wild type C57BL6 mice and can be induced in two-
month-old Cx3cr1-/- mice by exposure to 100 Klux for
10 min, which does not provoke degeneration in wild
type C57BL6 mice [19,53]. Cx3cr1-/- mice on an albino
Balb genetic background develop complete light-depen-
dent photoreceptor degeneration by the age of four
months in 12 h/24 h 100-500 lux (normal animal facility
conditions). In a light-induced model that provokes near
complete degeneration in pigmented C57Bl6 wild type
animals this difference is no longer observed [63], sug-
gesting that a maximal MC/Mj cell toxicity can be
reached in wild type animals. Activated MC toxicity has
been shown in photoreceptors in vitro [64] and in vivo
[23]. Neuronal cell toxicity caused by the prolonged pre-
sence of activated Cx3cr1-/- MCs in the brain has been
described as a mechanism of neurodegenerative diseases
[65]. Similar mechanisms may cause the degeneration
observed in the Cx3cr1-/- mice.
Additionally, Cx3cr1-/- mice develop increased MC/
Mj accumulation and choroidal neovascularization in
comparison to controls in a laser-induced choroidal
neovascularization (CNV) model, suggesting that the
presence of subretinal MC/Mjs contributes to a proan-
giogenic environment [19]. MC/Mjs might produce
proangiogenic factors themselves, but more importantly,
they have been shown to induce MMP9 and VEGF
expression in the RPE [42]. This may help to explain
the increase in CNV observed in Cx3cr1-/- mice.
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In summary, Cx3cr1-/- mice develop primary subret-
inal MC accumulation, possibly resulting from a migra-
tory defect associated with CX3CR1 dysfunction. We
have shown that the M280 polymorphism of CX3CR1,
associated with AMD increases adherence to its ligand
[50]. The increased adherence to transmembraneous
CX3CL1 abundantly present in the retina and RPE [34]
significantly inhibits the mobility of monocytes expres-
sing the CX3CR1-M280 variant [19]. If similar altera-
tions occur in vivo to MC/Mj, the M280 polymorphism
may cause excessive MC/Mj adherence to membrane-
anchored CX3CL1 in the retina and RPE [34] and
reduce migration in response to other inflammatory
chemoattractants. In subjects with the M280 poly-
morphism, clearance of MC/Mjs from the subretinal
space (in response to soluble CX3CL1 or other che-
moattractants) would thereby be inhibited, and subret-
inal MC/Mj accumulation might occur.
The prolonged presence of subretinal MC/Mjs could
thereby lead to subretinal drusenoid deposits, retinal
and RPE degeneration, and an increase in CNV as
observed in Cx3cr1-/- mice. These results suggest that
MC/Mj accumulation in the subretinal space may be a
driving force in the pathogenesis of AMD and not a
mere consequence of primary RPE or photoreceptor
disease.
Ccl2-/- and Ccr2-/- mouse models of AMD
There are several reports using Ccl2-/- or Ccr2-/- mice in
an attempt to decipher the inflammatory mechanisms of
AMD. CCL2 is increased intraocularly in exudative
AMD [47] and in a mouse model of choroidal neovascu-
larization [40]. Tsutsumi et al. [44] reported that macro-
phages extracted from eyes undergoing the laser-
induced CNV model are angiogenic and that the recruit-
ment of MC/Mjs to the injury site and subsequent
CNV are reduced in Ccr2-/- mice. These results have
since been corroborated in Ccl2-/- mice [45]. Supporting
this data is the repeated observation that macrophage
depletion inhibits CNV [24,66]. In contrast, Ambati et
al. observed spontaneous CNV in 4 of 15 Ccl2-/- and 3
in 13 Ccr2-/- mice older than 18 months of age, identi-
fied by angiographic leakage. Luhmann et al. were
unable to detect spontaneous CNV by angiography or
immunohistochemistry in 11 Ccl2-/- mice aged 16 to 25
months [45], suggesting that CCL2 deficiency is not suf-
ficient to induce spontaneous neovascularization.
Ambati et al. also observed the spontaneous appearance
of yellowish white subretinal deposits in fundoscopies of
Ccl2-/- and Ccr2-/- mice aged 9 months and older,
which they referred to as “drusen”. The authors sug-
gested that the deficiency in Mj recruitment through a
CCL2-/CCR2-dependent pathway from choroidal circu-
lation may prevent the clearance of accumulating debris
in BM [25], which, over time, would lead to drusen for-
mation. Luhmann et al. corroborated the spontaneous
appearance of funduscopically observed autofluorescent
lesions that resemble drusen in 16- to 25-month-old
Ccl2-/- mice. However, these lesions are not caused by
the sub-RPE extracellular deposits believed to be the
origin of drusen appearance in humans. In fact, the ana-
tomical equivalent of the lesions observed in Ccl2-/-
mice was found to be bloated subretinal lipid MC/Mjs
detectable by immunohistochemistry [45], similar to
those described in Cx3cr1-/- mice [19,56]. It is difficult
to appreciate what structure led to the drusen-like
lesions described by Ambati et al. [25] because immuno-
histochemical analysis of subretinal MC/Mjs were not
performed and no histological evidence of typical con-
vex shaped local BM deposits are shown.
In terms of photoreceptor degeneration Ambati et al.
[25], using electron microscopy, observed pyknotic
photoreceptor cell nuclei in 16-month-old Ccl2-/- mice
but not in wild type animals. Nevertheless, the quantifi-
cation of photoreceptor in 23- to 25-month-old mice
performed by Luhmann et al. [45] showed no significant
degeneration in Ccl2-/- mice as compared to wild type
congeners, suggesting that Ccl2 invalidation does not
lead to significant photoreceptor degeneration.
The conclusion drawn from Ambati’s data [25], that
AMD develops because of a CCR2-dependent macro-
phage recruitment deficit and therefore a hypoinflam-
matory state, is in contradiction with a recent report of
increased intraocular CCL2 levels in AMD [47] and
abundant evidence of MC/Mj accumulation in AMD
[9,19-21]. Further studies are needed to identify the
additional factors that led to the discrepancy of Luh-
mann et al.’s and Ambati et al.’s results.
The Ccl2-/-Cx3cr1-/- mouse model of AMD
Tuo et al. [37] were the first to describe an association
between the T280M Cx3cr1 allele and AMD in 2004.
Shortly thereafter, Ambati et al. [25] reported that
Ccl2-/- and Ccr2-/- mice develop AMD-like features at
an advanced age. In an attempt to accelerate the devel-
opment of AMD-like features, Tuo et al. [67] generated
Ccl2-/-Cx3cr1-/- mice that indeed develop “drusen,” pig-
ment alterations, and retinal degeneration by the age of
6 weeks in 100% of mice. Nevertheless, independently
generated Ccl2-/-Cx3cr1-/- mice in our laboratory do not
present any of these features at 6 weeks of age, and are
indistinguishable from Ccl2-/-, Cx3cr1-/- and wild type
animals. Tuo and Chan [68] also reported an abnormal
mendelian segregation of the Ccl2-/-Cx3cr1-/- genotype,
poor reproduction, and progressive patchy skin depig-
mentation, all of which we have not encountered in the
generation of our Ccl2-/-Cx3cr1-/- mice [29]. Tuo et al.
[68] selected the founding breeding pair of their Ccl2-/-
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Cx3cr1-/- mice “with the most retinal drusen-like
lesions”. By selecting the founding breeding pair for
AMD-like features, the authors may have selected ani-
mals genetically predisposed to these lesions indepen-
dent of their Ccl2 or Cx3cr1 invalidation. The non-
reproducibility of the ocular and systemic features in
our Ccl2-/-Cx3cr1-/- mice, in which the breeding pairs
were not selected for any feature other than the genetic
invalidation of Ccl2 and Cx3cr1, suggests this is the
case. The conclusions concerning the implication of
CCL2 in the phenotype of this mouse strain should
therefore be taken with caution.
Conclusions and perspectives
CX3CL1 and CX3CR1 are robustly expressed in the
healthy retina. Their dysfunction leads to subretinal
MC/Mj accumulation with deleterious effects to the
RPE and photoreceptors. The association of AMD with
a polymorphism in the Cx3cr1 gene, leading to a dys-
functional CX3CR1 protein, and the observation that
MC/Mjs accumulate in the subretinal space in AMD
suggests that dysfunctional CX3CL1/CX3CR1 signaling
might play a role in the pathogenesis of AMD. However,
the mechanism that leads to the MC/Mj accumulation
remains obscure and further research is needed to iden-
tify the implicated actors.
In contrast, CCL2 and CCR2 expression in the healthy
retina is low. Injuries, such as laser impacts or retinal
detachment, lead to a CCL2/CCR2 dependent recruit-
ment of MC/Mj to the subretinal space with deleterious
effects to the photoreceptors and to the progression of
CNV [23,44]. A recent clinical study that shows an asso-
ciation of increased intraocular CCL2 levels and AMD
[47] supports the possible involvement of CCL2 in the
pathogenesis of AMD. It is not well understood if CCR2
is expressed in the healthy retina. The observation that
Ccl2-/- mice also develop subretinal MC/Mj accumula-
tion at a later stage might indicate an age-dependent
shift in populations of CX3CR1 + CCR2- microglia to
CX3CR1 + CCR2 + microglia and that at this later
stage, CCL2/CCR2 signaling is implicated in the clear-
ance of subretinal MC/Mjs similar to the phenomenon
observed in Cx3cr1-/- mice. These results would suggest
that the inhibition of CCL2/CCR2 signaling might have
a beneficial effect on CNV formation and MC/Mj asso-
ciated photoreceptor degeneration at an early stage of
AMD. More research is needed to determine if CCL2/
CCR2 inhibition is beneficial at a later stage.
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